Treatment with rokitamycin suppresses the lethality in a murine model of Escherichia coli O157:H7 infection

International Journal of Antimicrobial Agents

Volumn 21, Issue 5, 2003, Pages 471-477

  Hiramatsu, Kazufumi ^a   Murakami, Junko ^a   Kishi, Kenji ^a   Hirata, Norio ^a   Yamasaki, Tohru ^a   Kadota, Jun Ichi ^a   Shibata, Tetsuo ^a   Nasu, Masaru ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Escherichia coli O157:H7 infection; In vivo experiment; Rokitamycin; Treatment

Indexed keywords

KANAMYCIN; LEVOFLOXACIN; ROKITAMYCIN; VANCOMYCIN; VEROTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; CELL COUNT; COLITIS; COLON; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; ENTEROHEMORRHAGIC ESCHERICHIA COLI INFECTION; EPITHELIUM CELL; ESCHERICHIA COLI; FECES ANALYSIS; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; INOCULATION; KIDNEY; KIDNEY TUBULE NECROSIS; LETHALITY; MALE; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; FECES; MALE; MICE; MICE, INBRED C3H; MIOCAMYCIN; OFLOXACIN; SURVIVAL ANALYSIS;

EID: 0037404685     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00007-4     Document Type: Article

References (22)

1. Riley L.W., Remis R.S., Helgerson S.D., et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. New Engl. J. Med. 308:1983;681-685.
2. Dundas S., Todd W.T.A., Stewart A.I., Murdoch P.S., Chaudhuri A.K., Huchinson S.J. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin. Infect. Dis. 33:2001;923-931.
3. Fukushima H., Hashizume T., Morita Y., et al. Clinical experiences in Sakai city hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai city, 1996. Pediatr. Int. 41:1999;213-217.
4. Cody S.H., Glynn M.K., Farrar J.A., et al. An outbreak of Escherichia coli O157:H7 infection from unpasteurized commercial apple juice. Ann. Intern. Med. 130:1999;202-209.
5. Banatvala N., Griffin P.M., Greene K.D., et al. The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical, and epidemiologic findings. J. Infect. Dis. 183:2001;1063-1070.
6. Wadolkowski E.A., Sung L.M., Burris J.A., Samuel J.E., O'Brien A.D. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect. Immun. 58:1990;3959-3965.
7. Kita E., Yunou Y., Kurioka T., et al. Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7. Infect. Immun. 68:2000;1207-1214.
8. Richardson S.E., Rotman T.A., Jay V., et al. Experimental verocytotoxemia in rabbits. Infect. Immun. 60:1992;4154-4167.
9. Grif K., Dierich M.P., Karch H., Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 17:1998;761-766.
10. Walterspiel J.N., Ashkenazi S., Morrow A.L., Cleary T.G. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin 1. Infection. 20:1992;25-29.
11. Kimmitt P.T., Harwood C.R., Barer M.R. Induction of type 2 Shiga toxin synthesis in Escherichia coli O157 by 4-quinolones. Lancet. 353:1999;1588-1589.
12. Wong C.S., Jelacic S., Habeeb R.L., Watkins S.L., Tarr P.I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. New Engl. J. Med. 342:2000;1930-1936.
13. Mizukane R., Hirakata Y., Kaku M., et al. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38:1994;528-533.
14. Murakami J., Kishi K., Hirai K., Hiramatsu K., Yamasaki T., Nasu M. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int. J. Antimicrob. Agents. 15:2000;103-109.
15. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, PA, 1993.
16. Isogai E., Isogai H., Hayashi S., et al. Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection. Microbiol. Immunol. 44:2000;89-95.
17. Yoshimura K., Fujii J., Taniguchi H., Yoshida S. Chemotherapy for enterohemorrhagic Escherichia coli O157: H infection in a mouse model. FEMS Immunol. Med. Microbiol. 26:1999;101-108.
18. Zhang X., McDaniel A.D., Wolf L.E., Keusch G.T., Waldor M.K., Acheson D.W. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181:2000;664-670.
19. Yoh M., Frimpong E.K., Voravuthikunchai S.P., Honda T. Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. Can. J. Microbiol. 45:1999;732-739.
20. Karpman D., Connell H., Svensson M., Scheutz F., Alm P., Svanborg C. The role of lipopolysaccaride and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J. Infect. Dis. 175:1997;611-620.
21. Louise C.B., Obrig T.G. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1β, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect. Immun. 59:1991;4173-4179.
22. Murata A., Shimazu T., Yamamoto T., et al. Profiles of circulating inflammatory and anti-inflammatory cytokines in patients with hemolytic uremic syndrome due to E. coli O157 infection. Cytokine. 10:1998;544-548.